Dengue Vaccine Development and Deployment into Routine Immunization
Vaccines · 29.04.2025 · 13 (5) · 483
DOI: 10.3390/vaccines13050483 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 29.04.2025. Verfasst von Annelies Wilder-Smith und 2 weiteren Autor:innen. Beteiligte Einrichtung: World Health Organization, CH-1211 Geneva, Switzerland. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization.
Abstract (Originalsprache)
Dengue has emerged as a significant global health threat. Despite decades of research, only two dengue vaccines—CYD-TDV (Dengvaxia) and TAK-003 (Qdenga)—have been licensed to date, with limited implementation. This paper explores and outlines strategies for integrating dengue vaccines into routine immunization programs, particularly in high-burden regions. TAK-003, a tetravalent live-attenuated vaccine, has demonstrated 61% efficacy against virologically confirmed dengue and 84% efficacy against hospitalizations in endemic settings. However, concerns remain about vaccine-enhanced disease, particularly among seronegative individuals exposed to DENV3 and DENV4. WHO recommends targeted introduction in high-transmission settings without pre-vaccination screening, while ongoing post-introduction studies will further clarify long-term safety and efficacy. Effective vaccine rollout requires a multi-pronged approach, including school-based immunization, integration with adolescent health services, and strong community engagement. Decision-making for vaccine introduction should be guided by National Immunization Technical Advisory Groups (NITAGs), local epidemiological data, and cost-effectiveness assessments. While future vaccines, including mRNA and virus-like particle candidates, are under development, optimizing the use of currently available vaccines is crucial to reducing dengue’s public health impact. Given the continued rise in cases, immediate action—combining vaccination with vector control—is essential to prevent further morbidity and mortality.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- World Health Organization, CH-1211 Geneva, Switzerland.
ORCID-Profile: Thomas Cherian, Joachim Hombach
Förderung
- World Health Organization
Zitieren
APA
Wilder-Smith, A., Cherian, T., & Hombach, J. (2025). Dengue Vaccine Development and Deployment into Routine Immunization. Vaccines, 13(5), 483. https://doi.org/10.3390/vaccines13050483
Vancouver
Wilder-Smith A, Cherian T, Hombach J. Dengue Vaccine Development and Deployment into Routine Immunization. Vaccines. 2025;13(5):483. doi:10.3390/vaccines13050483
BibTeX
@article{WilderSmith2025,
author = {Wilder-Smith, Annelies and Cherian, Thomas and Hombach, Joachim},
title = {Dengue Vaccine Development and Deployment into Routine Immunization},
journal = {Vaccines},
year = {2025},
volume = {13},
number = {5},
pages = {483},
doi = {10.3390/vaccines13050483}
}
EUVIMED